Integrating anti-PD1/PD-L1 and SBRT notably improved survival in early-stage NSCLC patients154 but yielded disparate results in metastatic NSCLC, underscoring the impact of tumour volume and prior therapies in SBRT and ICI utilization. This evidence concerns the gene PDCD1 and neoplasm.